AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
49.5%+8.5 pts over 5 years
Operating margin
19.5%+16.4 pts over 5 years
Net margin
13.6%+13.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.7% | +13.0% | +15.5% | +11.1% | |
| Gross profit | -4.8% | +12.7% | +20.0% | +16.5% | |
| Operating income | -31.7% | +9.3% | +66.6% | – | |
| Net income | -38.5% | +2.4% | +133.8% | – | |
| EPS, diluted | -33.7% | +5.3% | +132.3% | – | |
| Free cash flow | -29.7% | +23.0% | +38.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 3.1% | 0.4% | – | |
| Return on assets | 2.4% | 0.2% | 6.1% | |
| Current ratio | 3.04 | 2.49 | 4.02 | |
| Debt to equity | 0.11 | 0.12 | – | |
| Net debt to EBITDA | – | -2.40× | – | |
| Interest coverage | 15.0× | 29.3× | 5.5× | |
| Inventory turnover | 2.0× | 2.0× | 2.2× | |
| Capex to revenue | 8.4% | 9.7% | 4.8% | |
| Diluted shares | 48M | 49M | 48M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Amphastar Pharmaceuticals generated $740.18M from operations and spent $453.55M on capital expenditure, dividends and share buybacks. 37% of that went back into the business.
Generated
$740.18M
Used
$453.55M
Capital expenditure$165.58M37%Dividends$00%Share buybacks$287.97M63%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin14.2%
×Asset turnover0.67×
×Equity multiplier1.54×
=Return on equity, FY202114.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2021 | 14.2% | 0.67× | 1.54× | 14.7% |
| FY2020 | 0.4% | 0.57× | 1.55× | 0.4% |
| FY2019 | 15.2% | 0.59× | 1.54× | 13.7% |
| FY2018 | -1.9% | 0.61× | 1.45× | -1.7% |
| FY2017 | 1.5% | 0.55× | 1.33× | 1.1% |
| FY2016 | 3.8% | 0.62× | 1.31× | 3.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$98.09M
- Cash generatingOperating cash flow above zero$156.12M
- Return on assets improvedROA up on the prior year10.5% → 6.2%
- Earnings backed by cashOperating cash flow above net income$156.12M vs $98.09M
- Less leverageLong-term debt to assets fell38.1% → 37.4%
- Better liquidityCurrent ratio rose3.07 → 4.02
- No dilutionShare count did not rise52M → 48M
- Gross margin improvedGross margin up on the prior year51.08% → 49.46%
- More efficientAsset turnover rose0.48 → 0.46